Key figures
| EUR 1,000 (unaudited) | Year 2020 | Year 2021 | Year 2022 | Year 2023 | Year 2024 |
|---|---|---|---|---|---|
| Net sales | 1,499 | 2,003 | 2,942 | 3,906 | 4,544 |
| Sales margin | 1,103 | 1,376 | 2,139 | 2,810 | 3,391 |
| Sales margin, % | 73.5% | 68.7% | 72.7% | 71.9% | 74.6% |
| EBITDA | -1,787 | -2,497 | -2,112 | -2,833 | -4,053 |
| EBIT | -1,925 | -2,666 | -2,292 | -3,034 | -4,202 |
| Profit/-loss for the period (+/-) | -2,259 | -6,017 | -2,416 | -3,789 | -4,614 |
| R&D spend on total costs, % | 23.6% | 34.7% | 28.1% | 25.6% | 28.7% |
| Equity ratio, % | 35.1% | 50.6% | 55.2% | 77.3% | 84.9% |
| Cash and cash equivalents | 2,273 | 6,621 | 1,223 | 6,901 | 6,289 |
| Earnings per share (undiluted) | -0.02 | -0.43 | -0.17 | -0.19 | -0.20 |
| Earnings per share (diluted) | -0.01 | -0.31 | -0.12 | -0.15 | -0.17 |
| Number of shares (undiluted)* | 150,402,068 | 14,111,858 | 14,111,858 | 19,536,858 | 23,336,858 |
| Number of shares (diluted)* | 218,724,369 | 19,679,006 | 19,608,126 | 24,908,133 | 27,515,133 |
| Personnel | 23 | 26 | 28 | 37 | 47 |
*A reverse stock split was executed in April 2021, as a result of which the number of the company’s shares was divided by 15
Better healing — better life
Connect
Contact us© 2025 Bioretec Ltd. All rights reserved. Specifications are subject to change without notice.
Privacy Policy